NasdaqGM:RAPPPharmaceuticals
1 Reason Rapport Therapeutics (RAPP) Looks Pricey Following Truist Buy Coverage
Coverage of Rapport Therapeutics (RAPP) has expanded after Truist Financial analyst Danielle Brill initiated research on the company, a move that often draws fresh attention from institutional and retail investors.
See our latest analysis for Rapport Therapeutics.
Rapport Therapeutics has attracted increased interest as the stock records a 42.30% year to date share price return and a very large 238.70% 1 year total shareholder return, suggesting momentum has built meaningfully in recent...